AMPH
NASDAQ
US
Amphastar Pharmaceuticals, Inc. - Common Stock
$20.45
▲ +$0.21
(+1.04%)
Vol 390K
11
Quality Score
ok
Deep Check
2/5
ok
Rev ✓
NI ✓
>IPO ✗
Mkt Cap
$1.2B
P/E
11.0
ROE
14.8%
Margin
15.4%
D/E
78.47
Beta
0.88
52W
$20–$40
Wall Street Consensus
13 analysts · Apr 20263
Strong Buy
5
Buy
5
Hold
0
Sell
0
Strong Sell
61.5%
Buy Rating
Price Chart
Similar Stocks
About Amphastar Pharmaceuticals, Inc. - Common Stock
Amphastar Pharmaceuticals, Inc. (AMPH) - це фармацевтична компанія, що спеціалізується на розробці, виробництві та маркетингу ін'єкційних та інгаляційних продуктів. Компанія займає нішу на ринку генеричних та брендових лікарських засобів, особливо в лікарняному сегменті. Ключовою перевагою є здатність розробляти складні генерики та ефективно виводити їх на ринок.
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $0.94 | $0.73 | $-0.21 |
| Sep 2025 | $0.84 | $0.93 | +$0.09 |
| Jun 2025 | $0.76 | $0.85 | +$0.09 |
| Mar 2025 | $0.70 | $0.74 | +$0.04 |
Quarterly Revenue & Earnings
| Quarter | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Revenue | $186.5M | $170.5M | $174.4M | $191.8M | $183.1M |
| Net Income | $38.0M | $25.3M | $31.0M | $17.4M | $24.4M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 18.1% | 18.1% | 18.1% | 18.1% | 14.8% | 14.8% |
| P/E (TTM) | 8.03 | 10.47 | 9.32 | 8.80 | 10.98 | 11.02 |
| Net Margin | 17.8% | 18.6% | 18.6% | 18.6% | 15.4% | 15.4% |
| Gross Margin | 49.6% | 49.9% | 49.9% | 49.9% | 49.4% | 49.4% |
| D/E Ratio | 80.35 | 80.35 | 80.35 | 80.35 | 78.47 | 78.47 |
| Current Ratio | 3.29 | 3.29 | 3.29 | 3.29 | 3.12 | 3.12 |
Key Ratios
ROA (TTM)
6.9%
P/S (TTM)
1.70
P/B
2.5
EPS (TTM)
$2.26
CF/Share
$3.20
Rev Growth 3Y
+18.7%
52W High
$39.56
52W Low
$20.39
$20.39
52-Week Range
$39.56
Financial Health
Free Cash Flow
$24.6M
Net Debt
$485.8M
Cash
$170.2M
Total Debt
$656.0M
As of Dec 31, 2025
How does AMPH compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
AMPH valuation vs Pharmaceuticals peers
P/E ratio
11.0
▼
51%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
1.7
▼
66%
below
peers
(5.0)
vs Peers
vs Industry
Undervalued
P/B ratio
2.5
▲
16%
above
peers
(2.1)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
AMPH profitability vs Pharmaceuticals peers
ROE
14.8%
▲
127%
above
peers
(-54.3%)
vs Peers
vs Industry
Top tier
Net margin
15.4%
▲
133%
above
peers
(-47.4%)
vs Peers
vs Industry
Below avg
Gross margin
49.4%
▼
28%
below
peers
(68.3%)
vs Peers
vs Industry
Weak
ROA
6.9%
▲
118%
above
peers
(-37.4%)
vs Peers
vs Industry
Top tier
AMPH financial health vs Pharmaceuticals peers
D/E ratio
78.5
▲
4995%
above
peers
(1.5)
vs Peers
vs Industry
High debt
Current ratio
3.1
▼
7%
below
peers
(3.4)
vs Peers
vs Industry
In line
Beta
0.9
▼
7%
below
peers
(0.9)
vs Peers
vs Industry
Less volatile
AMPH fundamentals radar
AMPH
Peer median
Industry
AMPH profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
AMPH vs peers: key metrics
Related Signals
Insider Activity
NeutralBuys
0
Sells
0
PETERS WILLIAM J
Chief Financial Officer · Mar 09
58693 shs
ZHANG JACK YONGFENG
Chief Executive Officer · Mar 09
252966 shs
ZHOU RONG
Officer · Mar 09
39432 shs
LIAWATIDEWI YAKOB
Officer and Director · Mar 09
35450 shs
Last 90 days
Top Holders
Top 5: 29.47%Blackrock Inc.
12.04%
$103.8M
Vanguard Group Inc
5.75%
$49.6M
TD Asset Management, Inc
4.33%
$37.3M
Dimensional Fund Advisors LP
3.97%
$34.2M
State Street Corporation
3.38%
$29.1M
As of Dec 31, 2025